Enlivex Secures $400M Private Placement at a Premium, Plus an Option for Another $400M
ENLV is trading near its 52-week low of $4.02 (14% below the low).
Summary
Enlivex announced a $400M private placement priced at a premium to market, with an option to require the investor to purchase up to another $400M over 36 months. The investor elected to pay in RAIN tokens, reinforcing the company's prediction markets treasury strategy.
Key Events · Financing and Capital Events · ENLV
-
$400M Private Placement at Premium
Enlivex entered into a securities purchase agreement with a single institutional investor for $400M of ordinary shares at $5.00/share (USD/USDT/USDC) or $6.00/share (RAIN tokens), representing a 17.4% and 40.8% premium to the July 27 closing price, respectively. The investor elected to fund with RAIN tokens.
-
Additional $400M Put Right
The agreement grants Enlivex a 36-month right, but not obligation, to require the investor to purchase up to an additional $400M on the same pricing terms, potentially bringing total proceeds to $800M.
-
Shareholder Approval Required
Closing is subject to shareholder approval under Nasdaq Listing Rules 5635(a) and 5635(b) and Section 274 of the Israeli Companies Law. The company expects to close promptly after approval.
-
Use of Proceeds
Net proceeds will fund the company's prediction markets treasury strategy built around the Rain protocol and advance Allocetra™, its clinical-stage immunotherapy for age-related osteoarthritis.
Analysis · ENLV · Life Sciences
Enlivex has locked in a $400 million private placement from a single institutional investor, priced at $5.00 per share—or $6.00 if funded in RAIN tokens—both representing a premium to the July 27 closing price. The investor chose to pay in RAIN tokens, aligning the deal with the company's prediction markets treasury strategy. Under the agreement, Enlivex also holds a 36-month put right that can require the investor to purchase up to an additional $400 million on the same terms, potentially doubling the total raise to $800 million. Closing is subject to shareholder approval. For a company with a $71.7 million market cap, this is a transformative capital injection that provides substantial runway for both its clinical programs and digital asset strategy. The premium pricing signals strong institutional confidence, but the sheer size of the offering—over 5x the current market cap—will result in massive dilution if fully exercised.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.7M. The 52-week trading range was $4.02 to $31.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.